2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
19
Neoplasm Metastasis
2
Prostatic Neoplasms, Castration-Resistant
1
Prostate Adenocarcinoma
1
Pain
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Metastatic Castration-resistant Prostate Cancer
1
Fatigue
1
Castration-resistant Prostate Cancer
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Biochemical Recurrent Prostate Cancer
1
Interventions
Abiraterone Acetate
7
enzalutamide
6
olaparib
5
Prednisone
5
Pluvicto
5
Docetaxel
5
radium Ra 223 dichloride
4
darolutamide
4
cabazitaxel
3
Prednisolone
3
testosterone 17 beta-cypionate
2
fludarabine
2
abiraterone
2
Nivolumab
2
Cyclophosphamide
2
Androgen Antagonists
2
sipuleucel-T
1
rucaparib
1
poly ICLC
1
pamiparib
1
niraparib
1
lactitol
1
fludarabine phosphate
1
fluciclovine F-18
1
enfortumab vedotin
1
ebastine
1
copanlisib
1
cabozantinib
1
bempegaldesleukin
1
avelumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Castration-resistant Prostate Cancer
×
Radium-223
×
Clear all
NCT04109729
2026-06-01
Rad2Nivo
University of Utah
Phase 1
Active not recruiting
39 enrolled